847-869-1500 
How Neuroscience Informs Treatment
6:00PM - 7:30PM Presentation
In Person and Live Webinar
Colleagues & Conversations @ Yellowbrick
How Neuroscience Informs Treatment
Presented by David Baron, MD
September 16, 2025 | 6pm-7:30pm CST
In Person and Live Webinar
In Person Event at Yellowbrick
Synchrony Open House (located within the Yellowbrick offices)
Come tour Synchrony’s neuromodulation services (dTMS, Neurofeedback and other interventions) and meet with our clinical staff
5:00pm – 6:00pm
Prior to Colleagues & Conversations
Yellowbrick is located at:
1560 Sherman Avenue
Evanston, Illinois 60201
Live Webinar
6:00pm – 7:30pm
1.5 CEU Credits offered through Trusted Provider Network
No Charge
Educational Goal
The educational goal of this presentation is for participants to gain an understanding of the science and application of several newer neuromodulatory treatments, including deep Transcranial Magnetic Stimulation, Neurofeedback, Cranial Electrotherapy Stimulation, and novel medication such as es-ketamine (Spravato), and to become aware of the synergistic effects these treatments, as well as one way to objectively measure objective outcome using before and after Quantitative EEG.
Conference Description:
Clinical outcomes from the traditional psychiatric approach of medications and therapy are often insufficient. Researched innovations in neuromodulation technologies, including deep TMS, neurofeedback, cranial electrotherapy stimulation, genetically informed and novel medications like es-ketamine (Spravato), are safe and enhance outcomes. These neuroscience technologies can make the difference between partial recovery and full relief and freedom. This presentation will describe how such approaches can be coordinated in an outpatient setting, Synchrony Brain Health, either in concert with ongoing therapies or as an alternative to them.
Learning Objectives:
- Summarize the limitations of current standards for FDA approval of antidepressants.
- Describe the basic scientific principles behind transcranial magnetic stimulation, quantitative electroencephalography (QEEG), neurofeedback and cranial electrotherapy stimulation.
- Evaluate the relevance of post-treatment QEEG as a measure of treatment outcome reflecting improvements in brain dysregulation.
- List at least two benefits of pharmacogenomic testing to treatment decisions about supplements and choice of pharmacotherapy.
Presenter
David Baron, MD
David Baron, MD, was born and raised in part in New York City, and later in Livingston, New Jersey. He received his B.A. in Psychology (magna cum laude) and M.D. degrees from Case Western Reserve University in Cleveland, Ohio. Dr. Baron went on to complete his psychiatry residency at Tufts/New England Medical Center in Boston, Massachusetts.
Dr. Baron is a Clinical Assistant Professor at Rosalind Franklin University/The Chicago Medical School. In that role, he supervised psychiatric residents in their community psychiatry rotation for 15 years. He also served as Administrative Psychiatrist, and Interim Director of Mental Health Services, for the DuPage County Health Department, supervising 50 psychiatrists and over 200 other clinical staff.
Dr. Baron’s clinical and administrative experience, including nearly 25 years in private practice, since completing his training in 1989 has been within a developmental neurobiological understanding of mental illness. Over the course of his career, he has worked to understand mind and brain as different languages for the same essential human experience, including the complexity of neuroscience, the evolutionary basis of the human brain and behavior, and the deeply personal subjective experience of every individual.
Dr. Baron has been part of the Yellowbrick professional staff since 2012, serving as Medical Director since 2015. In this capacity he has led a team of seasoned and dedicated professionals in the intensive treatment of troubled Emerging Adults, using a multidisciplinary and integrated approach. This has allowed him to participate in treatment that taps a wide range of scientifically supported psychotherapeutic and neurobiological resources within the context of a supportive and non-restrictive therapeutic community, including a supported Residence.
Dr. Baron is certified by the American Board of Psychiatry and Neurology and is a Distinguished Life Fellow of the American Psychiatric Association. He served on the Ethics Committee of the Illinois Psychiatric Society as a member from 2001 to 2006, and as Chairman from 2006 to 2011.
Questions:
Call Tracy Ashworth 847-869-1500 ext. 207
Take the Next Step
Yellowbrick collaborates with adolescents and emerging adults, ages 16-30's, their families and participating professionals toward the development and implementation of a strategic “Life Plan.” An integrative, multi-specialty consultation clarifies strengths, limitations, and risks, and defines motivations, goals and choices.
Affiliations
847-869-1500